Gout Therapeutics Market Size, Share, And Growth Report 2032

Gout Therapeutics Market

Gout Therapeutics Market By Drug Condition (Antihyperuricemic Agents, Colchicine, Non-Steroidal Anti-Inflammatory Drugs, Corticosteroids, and Biologics), By Disease Condition (Acute Gout and Chronic Gout), By Distribution Channel (Hospital Pharmacy, Online Sales, and Retail Pharmacy), and By Region - Global And Regional Industry Overview, market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024–2032

Category: Pharmaceutical Report Format : PDF Pages: 130 Report Code: ZMR-4833 Published Date: Oct-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 2.61 Billion USD 4.52 Billion 6.3% 2023

Gout Therapeutics Market: Size

The global Gout Therapeutics Market size was worth around USD 2.61 billion in 2023 and is predicted to grow to around USD 4.52 billion by 2032 with a compound annual growth rate (CAGR) of roughly 6.3% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Gout Therapeutics Market on a global and regional level.

Global Gout Therapeutics Market SizeRequest Free Sample

Gout Therapeutics Market: Overview

Gout is a type of disease caused by frequent occurrences of acute inflammatory arthritis. The symptoms of this disease include red and itchy skin, swollen joints, and limited movement of the affected body parts. Additionally, due to uric acid crystallization and its deposit in tendons adjacent tissues and joints also leads to gout attack. The human body produces some amount of uric acid when it is broken down into purines. It is caused due to a combination of diet and genetic factor. Usually, a person who consumes large amounts of beer and meat shows or gets affected by the symptoms related to this disease.

Due to changing lifestyle, there has been a rise in the prevalence of gout across the globe that has boosted the gout therapeutics market growth. Rising consumption of alcohol, purine-rich diet, growing kidney diseases and obesity worldwide, and rising consumption of certain type of medication like the diuretics are likely to further boost gout incidence. Moreover, the growing adoption of biologics due to their ability to produce powerful anti-inflammatory action will also contribute to the gout therapeutics market in the future. Various drugs in clinical trials currently are expected to be launched over the forecast period, which will further propel this market. Additionally, new product launches and progressive collaboration between leading companies will positively impact this market. However, patent expiry and strict regulations of various drugs may hinder the gout therapeutics market on a global scale.

Global Gout Therapeutics MarketRequest Free Sample

Gout Therapeutics Market: Segmentation

The study provides a decisive view of the gout therapeutics market by segmenting it based on drug type, disease condition, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

On the basis of drug type, the market includes antihyperuricemic agents, colchicine, non-steroidal anti-inflammatory drugs, corticosteroids, and biologics.

On the basis of disease condition, the gout therapeutics market is bifurcated into acute gout and chronic gout.

By distribution channel, the market comprises hospital pharmacy, online sales, and retail pharmacy.

Gout Therapeutics Market: Report Scope

Report Attributes Report Details
Report Name Gout Therapeutics Market
Market Size in 2023 USD 2.61 Billion
Market Forecast in 2032 USD 4.52 Billion
Growth Rate CAGR of 6.3%
Number of Pages 130
Key Companies Covered Teijin Pharma, Takeda Pharmaceutical, Novartis, Mylan, Horizon Pharma, Teva Pharmaceutical, Iroko Pharmaceuticals, Hikma Pharmaceuticals, and Merck
Segments Covered By drug type, By disease condition, By distribution channel and By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2023
Historical Year 2018 to 2022
Forecast Year 2024 - 2032
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Gout Therapeutics Market: Regional Analysis

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Europe and North America are leading regions that dominate the gout therapeutics market globally, due to the enhanced pharmaceutical research in these areas. North America is among the leading players in the market for gout therapeutics, due to a rising geriatric population base along with modernized routine disorders. Additionally, the U.S. holds the largest share for gout therapeutics market across entire North America. The Asia Pacific region is likely to witness the highest rate of growth over the forecast period in the gout therapeutics market, owing to the rising regional awareness about the disease.

Gout Therapeutics Market: Competitive Players

Some key players in the global gout therapeutics market include:

  • Teijin Pharma
  • Takeda Pharmaceutical
  • Novartis
  • Mylan
  • Horizon Pharma
  • Teva Pharmaceutical
  • Iroko Pharmaceuticals
  • Hikma Pharmaceuticals
  • Merck

The Global Gout Therapeutics Market is segmented as follows:

Global Gout Therapeutics Market: Drug Type Analysis

  • Colchicine
  • Antihyperuricemic Agents
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Biologics

Global Gout Therapeutics Market: Disease Condition Analysis

  • Acute Gout
  • Chronic Gout

Global Gout Therapeutics Market: Distribution Channel Analysis

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Sales

Global Gout Therapeutics Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Gout is a type of disease caused by frequent occurrences of acute inflammatory arthritis. The symptoms of this disease include red and itchy skin, swollen joints, and limited movement of the affected body parts. 

According to study, the Gout Therapeutics Market size was worth around USD 2.61 billion in 2023 and is predicted to grow to around USD 4.52 billion by 2032.

The CAGR value of Gout Therapeutics Market is expected to be around 6.3% during 2024-2032.
 

Europe and North America has been leading the Gout Therapeutics Market and is anticipated to continue on the dominant position in the years to come.

The Gout Therapeutics Market is led by players like Teijin Pharma, Takeda Pharmaceutical, Novartis, Mylan, Horizon Pharma, Teva Pharmaceutical, Iroko Pharmaceuticals, Hikma Pharmaceuticals, and Merck.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

twitter

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed